Investors/Media

Investors / Media

Webcast ImageWebcast
Q1 2017 Infinity Pharmaceuticals, Inc. Earnings Conference Call (Live)
05/09/17 at 4:30 p.m. ET
Q1 2017 Infinity Pharmaceuticals, Inc. Earnings Conference Call
Tuesday, May 9, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways.

Stock Chart

More »
Stock chart for: INFI.O.  Currently trading at $2.10 with a 52 week high of $6.29 and a 52 week low of $0.84.

Recent Events

View all events »
Q1 2017 Infinity Pharmaceuticals, Inc. Earnings Conference Call
May 09, 2017 4:30 p.m. ET
Q4 2016 Infinity Pharmaceuticals, Inc. Earnings Conference Call
Mar 14, 2017 4:30 p.m. ET
Infinity Pharmaceuticals, Inc. at Cowen and Company 37th Annual Health Care Conference
Mar 06, 2017 4:00 p.m. ET

Recent Releases

More >>
Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast
Apr 26, 2017
CAMBRIDGE, Mass., April 26, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 9, 2017, at 4:30 p.m. ET to review its first quarter 2017 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five min... 
Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017
Apr 01, 2017
- IPI-549 Was Well Tolerated as a Monotherapy and in Combination with Opdivo® in Patients with Advanced Solid Tumors - - Phase 1 Expansion Modules Expected to Initiate in the Second Half of 2017 - WASHINGTON, April 1, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated Phase 1 clinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). These Phase 1 cl... 
Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results
Mar 14, 2017
- Updated Data from Phase 1 Study of IPI-549 to Be Presented at AACR - - Patient Enrollment in Combination Dose-Escalation Portion of IPI-549 Phase 1 Study Ongoing - - Phase 1 Expansion Cohorts Expected to Initiate in the Second Half of 2017 - CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full-year 2016 financial results and provided an update on the company, including its progress with IPI-549, a potentially first-i... 
 

INFI (Common Stock)

Price:$2.10
Change: - 0.04 (1.87%)
Intraday High:$2.17
Intraday Low:$2.07
Volume:412,889
Apr 27, 2017 at 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Annual Report

2016 Annual Report
Data Provided by Thomson Reuters